Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.

[1]  T. Pumarola,et al.  Immunohistochemically proven cytomegalovirus end‐organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests , 2007, Transplant infectious disease : an official journal of the Transplantation Society.

[2]  M. Schnitzler,et al.  Prophylactic Versus Preemptive Oral Valganciclovir for the Management of Cytomegalovirus Infection in Adult Renal Transplant Recipients , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  Nina Singh,et al.  Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy , 2006, Reviews in medical virology.

[4]  D. Snydman.  The case for cytomegalovirus prophylaxis in solid organ transplantation , 2006, Reviews in medical virology.

[5]  A. Limaye,et al.  Impact of Cytomegalovirus in Organ Transplant Recipients in the Era of Antiviral Prophylaxis , 2006, Transplantation.

[6]  J. Pérez,et al.  Recomendaciones GESITRA-SEIMC y RESITRA sobre prevención y tratamiento de la infección por citomegalovirus en pacientes trasplantados , 2005 .

[7]  M. Pescovitz,et al.  Clinical Utility of Cytomegalovirus (CMV) Serology Testing in High‐risk CMV D+/R− Transplant Recipients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  T. Popow-Kraupp,et al.  Antibody maturation and viremia after primary cytomegalovirus infection, in immunocompetent patients and kidney-transplant patients. , 2004, The Journal of infectious diseases.

[9]  B. Alexander,et al.  Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  S. Hossain,et al.  Cytomegalovirus Disease in High‐Risk Transplant Recipients Despite Ganciclovir or Valganciclovir Prophylaxis , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  P. Griffiths,et al.  Definitions of cytomegalovirus infection and disease in transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  D. Schoenfeld,et al.  Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis , 2000, Transplant infectious disease : an official journal of the Transplantation Society.